ImmuPharma PLC (LON:IMM)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 100 ($1.31) and last traded at GBX 92.50 ($1.22), with a volume of 376,672 shares. The stock had previously closed at GBX 79.50 ($1.05).
A number of equities analysts have issued reports on the company. Northland Securities reiterated a “buy” rating and set a GBX 181 ($2.38) price target on shares of ImmuPharma PLC in a research report on Wednesday, October 4th. Northland Capital Partners reiterated a “buy” rating and set a GBX 181 ($2.38) price target on shares of ImmuPharma PLC in a research report on Thursday, September 21st.
The firm’s 50-day moving average is GBX 56.50 and its 200-day moving average is GBX 53.93. The stock’s market cap is GBX 116.57 million.
About ImmuPharma PLC
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.